Clinical Trials Insight: 700052535

Trial Profile

Clinical Trials Insight: 700052535

Planning
Phase of Trial: Phase II/III

Latest Information Update: 27 Feb 2010

At a glance

  • Drugs Cytarabine; Laromustine
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Vion Pharmaceuticals
  • Most Recent Events

    • 27 Feb 2010 In response to the SPA filing for this phase II/III trial, the FDA requested that Vion conduct a separate phase II trial prior to initiation of a phase III trial, according to a Vion media release.
    • 14 Jan 2010 New trial record
    • 12 Jan 2010 According to a Vion Pharmaceuticals media release, a Special Protocol Assessment has been filed in response to the FDAs complete response letter to the Companys New Drug Application for Onrigin for the treatment of AML.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top